On Wednesday, the Swedish Public Health Agency recommended a temporary halt to the use of the Modern COVID-19 vaccine among young adults, with reference to concerns about rare side effects in the heart.
Stockholm -The Swedish Public Health Agency on Wednesday recommended a temporary stop to the use of the Modern COVID-19 vaccine among young adults, with reference to concerns about rare side effects in the heart. It said that the break would initially apply until December 1 and explained that it had received evidence of an increased risk of side effects such as inflammation of the heart muscle (myocarditis) and inflammation of the pericardium (pericarditis).
“The Public Health Agency has decided to suspend the use of the Maternal Vaccine Spike Vaccine, for all born in 1991 and after, for precautionary reasons,” the agency said in a statement, adding that these groups should receive the Pfizer / BioNTech vaccine instead.
According to the agency, the risk seemed particularly linked to the second dose of the Moderna vaccine and was more widespread among young men and boys, and in the weeks just after the second bite. The symptoms usually go away on their own, but should be evaluated by a doctor, it added.
In June, the US FDA said it was adding a warning to both Pfizer and Modern vaccines after a CDC advisory panel said data is suggested a “likely link” between the vaccines and rare cases of myocarditis in adolescents and young adults. Despite the warning, doctors and researchers say they still strongly recommend that all Americans 12 years and older be vaccinated, noting that heart problems are unusual and in most cases very mild.
Some COVID images may be associated with a rare heart …
Two separate vaccines studies then completedhowever, that COVID-19 itself poses a higher risk of symptoms, including myocarditis, than vaccines.
“Those who have been vaccinated recently, with their first or second dose of Moderna’s vaccine, do not have to worry because the risk is very small, but it is good to know what symptoms you should be on the lookout for,” said epidemiologist Anders Tegnell in a statement.
About 81,000 people in the age group have already received a first shot in Sweden, but they will not be offered a second, the agency said, adding that “discussions are ongoing about the best solution for this group.”
The European Medicines Agency (EMA) approved the emergency use of Moderna’s Covid-19 vaccine for teenagers in July.